Skip to search formSkip to main contentSkip to account menu

rivoglitazone

An agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity.
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Thiazolidinediones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Possible role of rivoglitazone thiazolidine class of drug as dual-target therapeutic agent for bacterial infections: An in silico study.
2013
2013
Stereoselectivity in pharmacokinetics of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys: model-based pharmacokinetic analysis and in vitro-in vivo…
Stereoselectivity in pharmacokinetics of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and… 
2012
2012
A 26‐week, placebo‐ and pioglitazone‐controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus
To evaluate the efficacy and safety of rivoglitazone, a peroxisome proliferator‐activated receptor γ agonist in the… 
2011
2011
A randomized‐controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose–lipid control in type 2 diabetes
Aim: To examine the efficacy, safety and tolerability of rivoglitazone, a novel thiazolidinedione (TZD), and explore its effects… 
2011
2011
Dynamic Changes of Adiponectin and S100A8 Levels by the Selective Peroxisome Proliferator–Activated Receptor-γ Agonist Rivoglitazone
Objective—Accumulating evidence indicates that the regimen to increase adiponectin will provide a novel therapeutic strategy for… 
2010
2010
A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes
Abstract Objective: To examine the efficacy and general safety of rivoglitazone, a novel thiazolidinedione, as a treatment for… 
2009
2009
Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
The pharmacological effects of rivoglitazone, a novel thiazolidinedione-derivative peroxisome proliferator-activated receptor… 
2008
2008
Model‐Based Development of a PPARγ Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs
A model‐based approach was implemented for the development of the proliferator‐activated receptor gamma (PPARγ) agonist… 
Review
2007
Review
2007
Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.
Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)